Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,259 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,094 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00034216 | Collection of Blood From Patients With Cancer | recruiting | — | 1,750 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00068003 | Harvesting Cells for Experimental Cancer Treatments | enrolling by invitation | — | 7,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02595957 | Genomic Services Research Program | recruiting | — | 5,000 | National Human Genome Research Institute (NHGRI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03364621 | Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy(COMPARISON) | active not recruiting | — | 17 | University Health Network, TorontoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04415853 | Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer | recruiting | Phase 3 | 416 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04645160 | Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers | recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | active not recruiting | Phase 3 | 461 | Mirati Therapeutics Inc.INDUSTRY | 32 | Sep 28, 2026 | clinicaltrials |
| NCT05872295 | IKS014 in Advanced Solid Tumors That Express HER2 | recruiting | Phase 1 | 165 | Iksuda Therapeutics Ltd.INDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT05903885 | A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans | active not recruiting | N/A | 1,200 | University of NebraskaOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05965999 | Lucid Registry Study(Lucid Registry) | recruiting | — | 8,000 | Lucid Diagnostics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06149481 | Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06388967 | Pancreatic Cancer Detection Consortium(PCDC) | recruiting | — | 2,000 | City of Hope Medical CenterOTHER | 3 | Sep 28, 2026 | clinicaltrials |
| NCT06454149 | Cohort Study for Gastric MALT Lymphoma(HUG-MALToma) | recruiting | — | 300 | Seoul National University HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06586957 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 238 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06726161 | Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC(GPC3) | recruiting | Phase 1 / Phase 2 | 590 | RayzeBio, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06803771 | Surveillance of Pancreatic Health After Diabetes Diagnosis(SAFE-D) | recruiting | N/A | 5,000 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06958432 | Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II) | recruiting | Phase 2 / Phase 3 | 430 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | recruiting | Phase 3 | 477 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT07039474 | The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy | recruiting | — | 120 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07221253 | A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)(AB02) | recruiting | Phase 3 | 1,100 | AstraZenecaINDUSTRY | 19 | Sep 28, 2026 | clinicaltrials |
| NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | recruiting | Phase 1 | 260 | IDEAYA BiosciencesINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07305428 | Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study | recruiting | N/A | 30 | The University of Hong KongOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07328516 | Natural History Study of Early Life Exposures in Agriculture (ELEA) | enrolling by invitation | — | 64,277 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07392892 | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | recruiting | Phase 2 / Phase 3 | 840 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07519655 | Phase 1 Study of PF-08046033 in Advanced Solid Tumors | recruiting | Phase 1 | 250 | PfizerINDUSTRY | 5 | Sep 28, 2026 | clinicaltrials |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )(RASolute 305) | recruiting | Phase 3 | 670 | Revolution Medicines, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT07691762 | A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 690 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | not yet recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07733180 | A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC | recruiting | Phase 2 | 30 | BeOne MedicinesINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844057 | First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma(FIRE-12) | not yet recruiting | Phase 2 | 86 | Annika KurreckOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02498613 | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | active not recruiting | Phase 2 | 122 | National Cancer Institute (NCI)NIH | 2 | Sep 25, 2026 | clinicaltrials |
| NCT02595931 | M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03516942 | Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment | active not recruiting | — | 565 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03702309 | Liquid Biopsy Evaluation and Repository Development at Princess Margaret(LIBERATE) | recruiting | — | 2,500 | University Health Network, TorontoOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04123379 | Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 2 | 48 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04858334 | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | recruiting | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 3 | Sep 25, 2026 | clinicaltrials |
| NCT04981119 | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing(BASECAMP-1) | recruiting | — | 500 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05610163 | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response(JANUS) | active not recruiting | Phase 2 / Phase 3 | 760 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 25, 2026 | clinicaltrials |
| NCT05687188 | Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations | active not recruiting | — | 185 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05922930 | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06004245 | A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 280 | Vividion Therapeutics, Inc.INDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT06005493 | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 392 | AstraZenecaINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06084234 | National Liver Cancer Screening Trial(TRACER) | recruiting | Phase 4 | 5,500 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06172478 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 2 | 740 | Daiichi SankyoINDUSTRY | 16 | Sep 25, 2026 | clinicaltrials |
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06218914 | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | recruiting | Phase 1 | 108 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
Data updated 24 hours agoSource updated Sep 28, 2026source: clinicaltrials